|
Sep 5
|
4DMT Announces Presentations at Upcoming Retina Conferences
|
|
Sep 3
|
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
|
|
Aug 27
|
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
|
|
Jun 24
|
4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment
|
|
Jun 24
|
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
|
|
Jun 18
|
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
|
|
Jun 8
|
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
|
|
Jun 6
|
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
|
|
May 11
|
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
|
|
May 11
|
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)
|
|
May 10
|
4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections
|
|
May 9
|
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
|
|
May 7
|
4DMT to Participate in Upcoming Investor Conference
|
|
May 1
|
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
May 1
|
4DMT Announces Presentations at ARVO 2024 Annual Meeting
|
|
Apr 4
|
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
|
|
Mar 29
|
4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
|
|
Mar 28
|
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
|
|
Mar 4
|
4DMT to Participate in Upcoming Investor Conferences
|
|
Feb 12
|
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
|